Brief Research Report
Published on 29 Apr 2021
Letermovir Administration to Prevent Cytomegalovirus Reactivation Is the Potential Risk of Chronic Graft-Versus-Host Disease in Patients Who Received Haploidentical Stem-Cell Transplantation With Post-Transplant Cyclophosphamide
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2021.666774
- 5,046 views
- 12 citations
